



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Scheffer, IE;Nabbout, R

Title:

SCN1A-related phenotypes: Epilepsy and beyond

Date:

2019-12-01

Citation:

Scheffer, I. E. & Nabbout, R. (2019). SCN1A-related phenotypes: Epilepsy and beyond. *Epilepsia*, 60 (S3), pp.S17-S24. <https://doi.org/10.1111/epi.16386>.

Persistent Link:

<https://hdl.handle.net/11343/286685>

Article type : Supplement Article

SCN1A related phenotypes: Epilepsy and beyond

Ingrid E Scheffer¹ and Rima Nabbout²

¹ Departments of Medicine and Paediatrics, The University of Melbourne, Austin Health and Royal Children's Hospital, Florey and Murdoch Children's Research Institute, Melbourne, Australia

² Reference Centre for Rare Epilepsies, Department of Paediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute U1163, Paris Descartes University, Paris, France

Corresponding author:

Prof. Rima Nabbout

Reference Centre for Rare Epilepsies, Department of Paediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute U1163, Paris Descartes University, Paris, France
rimanabbout@yahoo.com

Key words:

Dravet syndrome

hemiplegic migraine

Autism spectrum disorder

SUDEP

patients' centred outcomes

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as [doi: 10.1111/EPL.16386](https://doi.org/10.1111/EPL.16386)

This article is protected by copyright. All rights reserved

Key bullet:

- Dravet syndrome is the most well recognised epilepsy phenotype associated with *SCN1A*
- *SCN1A* has been implicated in other diseases such as hemiplegic migraine, autism spectrum disorder and SUDEP.
- Patients with Dravet syndrome should be evaluated for ASD that often present with a specific phenotype.
- Patients with Dravet Syndrome present with a complex disease showing many symptoms beyond epilepsy.

Abstract

SCN1A, encoding the alpha 1 subunit of the sodium channel, is associated with several epilepsy syndromes and a range of other diseases. *SCN1A* represents the archetypal channelopathy associated with a wide phenotypic spectrum of epilepsies ranging from Genetic Epilepsy with Febrile Seizures Plus (GEFS+), to developmental and epileptic encephalopathies (DEEs). *SCN1A* disorders also results in in other diseases such as hemiplegic migraine and autism spectrum disorder (ASD).

DS is the prototypic DEE with an early onset of febrile status epilepticus, hemiclonic or generalized tonic-clonic and later onset of additional seizure types. EEG and MRI are normal at onset. Development is normal in the first year of life but plateaus rapidly with most patients ultimately

having intellectual disability. Epilepsy is drug resistant and necessitates polytherapy. Most pathogenic variants occur *de novo* in the affected child, but they are inherited from mosaic affected or unaffected parents rare cases. The molecular finding of haploinsufficiency is consistent with a loss of function defect in cells and animal models. Although seizures are the most commonly reported symptom in DS, many additional issues critically impact on patients' cognitive and behavioural functioning.

Hemiplegic migraine (HM) is a rare form of migraine with aura, characterized by the emergence of hemiparesis as part of the aura phase. All *SCN1A* mutations reported in Sporadic/Familial HM3 are missense mutations. Most of the experimental results show that they cause a gain of function of Na_v1.1 as opposed to the loss of function of the epileptogenic Na_v1.1 mutations.

SCN1A and *SCN2A* pathogenic variants have been identified in genetic studies of cohorts of patients with ASD. In addition, ASD features are often reported in patients with Dravet syndrome and other DEEs.

Number of text pages: 13

Number of words (abstract): 277

Number of words (main text): 3240

Number of tables: 0

Number of figures: 0

SCN1A, encoding the alpha 1 subunit of the sodium channel, is associated with a range of human diseases. Since it was first implicated in epilepsy in 2000¹, *SCN1A* has remained the most important epilepsy gene. The most well recognized epilepsy phenotype associated with *SCN1A* is Dravet Syndrome, but it also results in several other epilepsy syndromes, many associated with significant co-morbidities. *SCN1A* has been implicated in other diseases such as hemiplegic migraine and autism spectrum disorder (ASD). Patients with Dravet Syndrome present with a complex disease showing many symptoms beyond epilepsies.

***SCN1A* Epilepsies**

SCN1A disorders represent the archetypal channelopathy associated with epilepsy. They result in a wide phenotypic spectrum ranging from self-limited and pharmaco-responsive

epilepsies, such as Genetic Epilepsy with Febrile Seizures Plus (GEFS+), to developmental and epileptic encephalopathies (DEEs). Even within the DEEs, there is a spectrum of severity ranging from Myoclonic-Atonic Epilepsy (MAE) to Dravet syndrome, Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) and Early Onset *SCN1A* DEE. Each has a different range of co-morbidities and prognosis, and intriguing evidence is emerging that they are underpinned by different functional deficits.

Dravet Syndrome

Dravet Syndrome is the prototypic DEE with a mean age of seizure onset of 6 months (upper age limit 15 months)². The infant typically presents with febrile seizures which may be a hemiclonic or generalised tonic-clonic seizure. First seizure can evolve to status in almost half of patients and is often followed by further convulsive seizures. If the infant has hemiclonic seizures, the lateralisation will often vary in different attacks, a critical clue to the diagnosis. Between one and five years of age, additional seizure types appear including focal impaired awareness seizures, absence seizures, myoclonic seizures and episodes of non-convulsive status epilepticus. The early occurrence of multiple seizure types, especially myoclonic seizures, have been shown to be a factor of negative prognosis. Overtime, seizures are might be less triggered by fever and tend to occur during sleep³. The EEG is often normal in the first one to two years of life, but then develops generalised spike wave, poly spike wave and multifocal discharges. Patients with Dravet Syndrome typically have drug resistant epilepsy.

Development is normal in the first year of life although some subtle development abnormalities are reported as oculo motor coordination deficit if infants undergo psychomotor testing. but plateaus between one and two years of age, with most patients ultimately having intellectual disability. The degree of intellectual disability varies from severe in about half of the patients, to moderate in the large majority of the others. Rare patients with mild learning disabilities or normal intellect have been recognised⁴. In terms of motor development, children walk a little late at 16-18 months, and they have more pronounced physiological ataxia. After puberty, they often develop subtle spasticity with a crouch gait⁵. Other issues in some patients include behaviour problems and autistic features. More than 80% of patients with Dravet Syndrome have pathogenic variants (or mutations) in *SCN1A*, making it the epilepsy syndrome with the highest yield on genetic testing⁶. About

half of the patients have truncation variants and half missense variants; genotype does not appear to be useful clinically helping to shape specific therapy or to predict prognosis⁷. While Sanger sequencing or next generation sequencing reveal most of the causative pathogenic variants, about 3% of patients have pathogenic copy number variants, either microdeletions or duplications that can be missed without appropriate testing⁸. Recently, a novel mechanism has been invoked where a poison exon, previously hidden in an intron, affects protein splicing in neurons⁹.

Most pathogenic variants occur *de novo* in the affected child, but in fewer than 10% of cases, they are inherited from mosaic affected or unaffected parents¹⁰. In some cases, they may inherit the pathogenic variant in a dominant manner in the setting of a family history of GEFS+¹¹. The molecular finding of haploinsufficiency is consistent with a loss of function defect in cells and animal models.

Myoclonic-Atonic Epilepsy (MAE)

Myoclonic-atonic epilepsy, described by Doose, is a genetic generalized epilepsy that begins in children aged between 7 months and 6 years, often with explosive onset of multiple seizure types¹². Seizures include the hallmark drop attacks due to myoclonic, atonic and myoclonic-atonic components. Other seizure types include absence seizures, generalized tonic-clonic seizures, and tonic seizures in the more severely affected children. Non-convulsive status epilepticus is common. The EEG shows 2-4 Hz generalized spike-wave activity; a 4-7 Hz theta rhythm is prominent in the parietal regions together with an occipital 4 Hz rhythm¹³. Outcome is highly variable, ranging from normal intellect to severe intellectual disability. Only a small percentage of patients with MAE have pathogenic variants in *SCN1A*, including the original GEFS+ family¹⁴. EMA phenotype was also reported in a few cases of *SCN2A*¹⁵.

Epilepsy of Infancy with Migrating Focal Seizures (EIMFS)

This rare disorder begins at a mean age of 2 months and is characterised by focal seizures which migrate clinically and electrically from one hemisphere to the other¹⁶. Seizures are extremely frequent and infants typically have profound developmental impairment. Rare patients with *SCN1A* mutations have been reported^{17; 18}. The major causal gene is *KCNT1*, responsible for almost half of cases¹⁹. However, this syndrome has emerged to be highly

genetically heterogeneous for another half of cases with more than 20 genes implicated, with most mutations arising *de novo*, although recessive inheritance is seen for specific genes.

Early Onset *SCN1A* DEE

This is the most severe of the *SCN1A* DEEs with seizures beginning at 8-12 weeks of age²⁰. Infants present with hemiclonic seizures or generalised tonic-clonic seizures. Epileptic spasms and tonic seizures are frequent in infancy and childhood; in contrast, epileptic spasms are not seen in Dravet Syndrome and nocturnal tonic seizures are not usually seen until adult life. Patients with this syndrome also have generalised tonic-clonic seizures, myoclonic seizures and convulsive status epilepticus. More cases and pathogenic variants were recently recognised with this but it is much less common than DS.

It is not clear if development is ever truly normal in these infants but developmental delay is apparent by 16 weeks of age. These children are far more profoundly impaired than children with Dravet Syndrome as they are non-verbal and non-ambulant. They develop a movement disorder between 9 weeks and 20 months of age which is hyperkinetic in nature with prominent chorea, dystonia and orofacial myoclonus. The EEG is initially normal but then develops generalised spike wave and multifocal epileptiform activity. To date most of the patients with this early onset *SCN1A* DEE have a recurrent *de novo* missense mutation, Thr226Met. There are other rare pathogenic variants that are being increasingly recognised that cause this profound syndrome.

From a mechanistic point of view, it is well known that Dravet Syndrome is associated with loss of *SCN1A* function. In contrast this early onset *SCN1A* DEE is associated with gain of function²¹. Thr226Met channels exhibit hyperpolarising shifts of both the activation and inactivation curves, together with enhanced fast inactivation. Berecki and colleagues found that current stimulation that produced repetitive action potential firing in control neurons, resulted in depolarisation block and cessation of action potential firing in Thr226Met model neurons. These physiological studies show that, from a biophysical perspective, the Thr226Met variant produces gain-of-function but, paradoxically, causes interneurons to more readily develop depolarisation block and produce a functional dominant negative interaction. It thereby produces more profound disinhibition compared with the haploinsufficiency that is characteristic of Dravet Syndrome. This profound phenotype has more corollaries with the

phenotypes of *SCN8A* encephalopathy and early infantile *SCN2A* encephalopathy, where children often have profound impairment associated with a severe movement disorder.

Genetic Epilepsy with Febrile Seizures Plus (GEFS+)

GEFS+ was first recognised in 1997 in large families with dominant inheritance of Febrile Seizures (FS) and self-limited, pharmacoresponsive seizure disorders in most family members²². FS is the most common phenotype in GEFS+ families, followed by Febrile Seizures Plus (FS+). FS+ refers to children where febrile seizures occur outside the normal limits of classical FS (6 months to 6 years) or where afebrile generalized tonic-clonic seizures occur as well as febrile convulsive seizures.

In GEFS+ families, there may be DEEs in some family members such as MAE and Dravet syndrome²³. Small and large families have been reported around the world and the heterogeneous spectrum of GEFS+ phenotypes have grown to include focal seizures without preceding FS and also Genetic Generalized Epilepsies²⁴.

SCN1A was first discovered in GEFS+ families¹. About 20% of reported families have pathogenic variants in *SCN1A*. GEFS+ does not always occur in a familial context; patients with GEFS+ phenotypes may have *de novo* *SCN1A* mutations²⁵. Comparing three genes implicated in GEFS+ families, *SCN1A*, *SCN1B* and *GABRG2*, *SCN1A* families had an earlier age of onset of FS and FS+ in the first year of life compared with families with *SCN1B* mutations, consistent with gene-specific effects²⁶.

Common epilepsies

Given the marked genetic heterogeneity of the epilepsies as a whole, large numbers of cases are required to assess if *SCN1A* is relevant to the common types of epilepsy. Two different approaches employed by large consortia have implicated *SCN1A* as playing a role.

Whole exome sequencing of a large number of unrelated individuals with the common epilepsies, genetic generalized epilepsies (GGE) and non-acquired sporadic epilepsies, sought to determine if there was an excess burden of rare genetic variation in all protein-encoding genes²⁷. They compared 525 familial and 662 sporadic non-acquired focal epilepsies with

3877 controls. Only *DEPDC5* showed genome-wide significance in familial cases, but *SCN1A* was fourth on the list of genes that showed more ultrarare variation than in controls, suggesting that it may become significant with a much larger number of cases. No gene showed genome-wide significance for the 640 familial GGE cases compared with 3877 controls, but *SCN1A* was seventh on the list and could become significant with far more cases. It was not surprising that the number of cases was underpowered to produce significant findings and whole exome sequencing of 20,000 cases is underway with the EPI25 consortium which promises to yield more significant results.

The International League Against Epilepsy Consortium on Complex Epilepsies performed a meta-analysis of genome-wide association studies on 8696 cases and 26,157 controls²⁸. When all patients with epilepsy were included, that is both GGE and focal epilepsy cohorts, a locus at chromosome 2q24.3 was identified. This finding implicates *SCN1A* and suggests it may act pleiotropically to raise the risk for epilepsy more broadly. This approach has recently been expanded to a genome-wide mega-analysis of 15,212 individuals with epilepsy compared with 29,677 controls and confirmed the chromosome 2q24.3 locus harbouring *SCN1A*²⁹. This locus is now significant for all epilepsies, GGE and focal epilepsies independently although it is not clear if the signal is due to several genes including *SCN1A*, *SCN2A* and *SCN3A*.

Non-epilepsy *SCN1A* Phenotypes

SCN1A pathogenic variants have also been reported in patients with other neurological disorders such as hemiplegic migraine and ASD. In patients with Dravet syndrome, the high frequency of ASD, gait disorders and Sudden Unexpected Death in Epilepsy (SUDEP) is also linked to *SCN1A* mutations and is supported by preclinical and clinical data.

Hemiplegic Migraine

Hemiplegic migraine is a rare form of migraine with aura and can be subdivided into familial hemiplegic migraine (FHM) and sporadic hemiplegic migraine (SHM). FHM is an autosomal dominant type of migraine with aura, characterized by the presence of hemiparesis as part of the aura phase. The clinical manifestations of hemiplegic migraine range from attacks with short-duration hemiparesis to severe forms with recurrent coma and prolonged hemiparesis,

permanent cerebellar ataxia, epilepsy, transient blindness, and mental retardation. Diagnosis relies on a careful patient history and exclusion of potential causes of symptomatic attacks³⁰. The pathophysiology of HM involves cortical spreading depression (CSD), a self-regenerating wave of transient neuronal hyperactivity leading to long-lasting (tens of seconds to a few minutes) neuronal and glial depolarization with suppression of firing propagating across the cortex at 2–3 mm/minute, much slower than epileptic discharges³¹.

Familial and sporadic HM (S/FHM) are caused by mutations of different genes. S/FHM3 is due to heterozygous pathogenic variants of the Nav1.1 voltage-gated sodium channel (*SCN1A*)³². Some genes have been implicated in both epilepsy and migraine³³, however, usually patients with FHM do not have seizures. Numerous studies have been undertaken to find out why a mutation in the same gene leads to different phenotypes³⁴.

Around 80 patients have been published carrying sporadic or familial FHM3 *SCN1A* mutations and few had both HM and epilepsy. In contrast to FHM due to *CACNA1A* and *ATP1A2* mutations, in the few patients with FHM3 carrying *SCN1A* mutations and presenting with seizures, HM attacks are always independent from seizures and in general the two phenotypes do not overlap temporally³⁴. Moreover, most of the pathogenic *SCN1A* mutations cause different types of epilepsy without migraine. The functional effect of the *SCN1A* mutations might partially explain the different phenotypes. Cellular and animal models of truncating and missense Nav1.1 mutations causing severe epileptic phenotypes cause complete loss of function of the channel, consistently with haploinsufficiency³⁵. This results in decreased excitability of GABAergic interneurons leading to reduced inhibition and network hyperexcitability, culminating in seizures³⁶. All *SCN1A* mutations reported in S/FHM3 are missense mutations. Most of the experimental results show that they cause a gain of function of Nav1.1³⁷. Cellular and animal data point to increased excitability of GABAergic neurons in S/FHM3, a different mechanism from that seen with epileptogenic Nav1.1 mutations.

Autism Spectrum Disorder (ASD)

Evidence from studies in familial and sporadic ASD has strongly pointed to a genetic etiology. *SCN1A* and *SCN2A* pathogenic variants have been identified in genetic studies of cohorts of patients with ASD³⁸. In addition, loss of function variants of these two genes were

significantly identified in one study targeting postmortem brain DNA sequencing of patients with ASD compared to controls ³⁹.

ASD features have been reported in patients with Dravet syndrome, but were defined as ‘autistic traits’ often without using standardized tools. Depending on the type of assessment, rates of ‘autistic traits’ vary from 8.3% to 61%⁴⁰. Most studies have reported lack of verbal communication with 10 to 79% of patients showing social problems, such as poor peer relationships, withdrawn behaviour, lack of emotional reciprocity, difficulty negotiating social rules and excessive familiarity³⁷. Restricted and unusual interests, like obsessions, perseverations or self-stimulation, are reported in 24 to 69% of patients ⁴¹.

Two studies assessed ASD in children with Dravet syndrome using standardized tools: the first with DSM-IV and ICD-10 criteria, the Childhood Autism Rating Scale diagnosis tool and Autism Behavior Checklist ⁴¹ and the second with gold standard tools (Autism Diagnosis Interview Revised, i.e. ADI-R or Autism Diagnosis Observation Scale 2, i.e. ADOS-2)⁴⁰. Both studies confirmed the occurrence of ASD in 24%-40% of children. This is lower than in an adult study where ASD was diagnosed in 61.5% ⁴². The underestimation of ASD in the pediatric series could be due to relative preservation of communicative and social skills such as social smiling, and a lower rate of the repetitive behavior typically seen in ASD ⁴⁰.

Scn1a^{+/-} mice are a well-defined Dravet syndrome model exhibiting both thermally-induced seizures and spontaneous seizures, in addition to other symptoms such as autism-like behavior ⁴³. Emerging data report a decrease in the autistic behavior of the DS animal model by enhancing GABAergic properties in inhibitory neurons ⁴⁴. Cannabidiol (CBD) showed a similar rescue effect of Dravet syndrome symptoms with increased inhibitory neurotransmission potentially mediated by GPR55 (G protein coupled receptor)⁴⁵. No human data are available to date on this possible improvement of social cognition with the therapies.

SUDEP (Sudden Unexpected Death in Epilepsy) and other SCN1A-related death

SUDEP is the most common cause of death that is related to epilepsy. It is defined as “a sudden, unexpected, witnessed or unwitnessed, non-traumatic, and non-drowning death in

patients with epilepsy with or without evidence for a seizure, and excluding documented status epilepticus, in which postmortem examination does not reveal a structural or toxicologic cause of death⁷⁴⁶. Data obtained from human studies and animal models have pointed to alterations in respiratory, cardiac, and brain function as three possible mechanistic areas in SUDEP⁴⁷. The report of two cases of SUDEP in a family with genetic epilepsy syndrome generalized epilepsy with febrile seizures plus (GEFS+) while segregating a novel variant in *SCN1A* gene is a rare example of familial SUDEP⁴⁸. The possible role of *SCN1A* in SUDEP is reported in animal models and human studies of patients with DS. Patients with DS face an increased risk of premature mortality estimated to affect about 4–12% of children⁴⁹⁻⁵¹. Patients with DS seem predisposed to SUDEP with the implication of autonomic dysfunction, as evidenced by depressed heart rate variability⁵²⁻⁵³ and increased P- and QT-interval dispersion⁵⁴. *Scn1a* deficient mice models mirror the human phenotype, exhibiting spontaneous seizures, autonomic instability, and seizure-driven vagal activation preceding sudden death⁵⁵⁻⁵⁶. Another mouse model carrying the human mutation *SCN1A-R1407X*⁵⁷ displayed a 21% premature death rate, spontaneous seizures, and a prolonged QT interval⁵⁷. Cardiac arrhythmias often preceded apparent convulsive seizures in this model indicating that some *SCN1A* variants could predispose to sudden death through neurocardiac or sole cardiac mechanisms^{57,58}.

The role of *SCN1A* dysfunction in sudden death without diagnosed epilepsy is also highlighted by a few cases. Two reports describe cases with sudden unexpected death in infancy and childhood with no previous reported epilepsy^{59,60}. The first report includes 2 cases of sudden infant death syndrome (SIDS) with no prior history of seizure with *SCN1A* variants, functionally shown to cause protein-altering changes in channel function⁵⁹. The other describes a case of sudden unexplained death in childhood (SUDC) in a child who was reported to have febrile seizures before dying suddenly and unexpectedly. His sibling was diagnosed with Dravet Syndrome due to a pathogenic variant in *SCN1A* that was thought to be *de novo*, and it was later found on a research basis that the father was mosaic and that the same pathogenic variant was present in the child who died⁶⁰.

Dravet syndrome: Core concepts beyond seizures

Cohort studies show that patients with Dravet syndrome and *SCN1A* mutations share features that go beyond purely seizures' related damage⁶¹. Patients present with developmental disability, behavioral and psychiatric disorders as well as gait disturbance and speech

disorder. Dravet syndrome impacts significantly on both patients' and caregivers' lives^{62,63}. We identified core domains to measure the impact on both patients and caregivers dealing with DS^{64,65}. Although seizures were the most commonly reported symptom in DS, many additional issues critically impact on patients' cognitive and behavioural functioning, as attested to by both caregivers and physicians. These issues might also have variable impact in relation to patient age⁶³. The five major domains of concern from French caregivers and healthcare professionals were: seizures, expressive communication and receptive communication of the child, impact on daily activities, and social functioning of the caregiver⁶⁴. This study was followed by further analysis of this conceptual disease model in four additional countries: USA, UK, Italy and Australia⁶⁵. Themes identified showed similarity with the French conceptual model with minor differences between countries that likely reflect variations in health care systems. These key impacts of Dravet syndrome on children and caregivers should be targeted as critical outcomes in the evaluation of new therapies.

Disclosure of Conflicts of Interest

None of the authors has any conflict of interest to disclose.

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

1. Escayg A, MacDonald BT, Meisler MH, et al. Mutations of *SCN1A*, encoding a neuronal sodium channel, in two families with GEFS+2. *Nat Genet* 2000;24:343-345.
2. Dravet C, Bureau M, Oguni H, et al. Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy). In Bureau M, Genton P, Dravet C, et al. (Eds) *Epileptic Syndromes in Infancy, Childhood and Adolescence*, John Libbey Eurotext: France; 2012:125-156.

3. Losito E, Losito E, Kuchenbuch M, Chemaly N, et al. Age-related "Sleep/nocturnal" tonic and tonic clonic seizure clusters are underdiagnosed in patients with Dravet Syndrome. *Epilepsy Behav.* 2017;74:33-40.
4. Vadlamudi L, Dibbens LM, Lawrence KM, et al. Timing of de novo mutagenesis--a twin study of sodium-channel mutations. *N Engl J Med* 2010;363:1335-1340.
5. Rodda JM, Scheffer IE, McMahon JM, et al. Progressive gait deterioration in adolescents with Dravet syndrome. *Arch Neurol* 2012;69:873-878.
6. Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 2001;68:1327-1332.
7. Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. *Brain* 2012;135:2329-2336.
8. Mulley JC, Nelson P, Guerrero S, et al. A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. *Neurology* 2006;67:1094-1095.
9. Carvill GL, Engel KL, Ramamurthy A, et al. Aberrant Inclusion of a Poison Exon Causes Dravet Syndrome and Related SCN1A-Associated Genetic Epilepsies. *Am J Hum Genet* 2018;103:1022-1029.
10. Myers CT, Hollingsworth G, Muir AM, et al. Parental Mosaicism in "De Novo" Epileptic Encephalopathies. *N Engl J Med* 2018;378:1646-1648.
11. Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. *J Med Genet* 2010;47:404-410.
12. Dooze H, Gerken H, Leonhardt R, et al. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. *Neuropadiatrie* 1970;2:59-78.
13. Guerrini R, Mari F, Dravet C. Idiopathic Myoclonic Epilepsies in Infancy and Early Childhood. In Bureau M, Genton P, Dravet C, et al. (Eds) *Epileptic Syndromes in Infancy, Childhood and Adolescence*, John Libbey Eurotext: France; 2012:1-17.
14. Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. *Am J Hum Genet* 2001;68:859-865.
15. Routier L, Verny F, Barcia G, et al. Exome sequencing findings in 27 patients with myoclonic-astatic epilepsy: Is there a major genetic factor? *Clin Genet.* 2019 Jun 6. doi: 10.1111/cge.13581. [Epub ahead of print]
16. Coppola G, Plouin P, Chiron C, et al. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. *Epilepsia* 1995;36:1017-1024.
17. Carranza Rojo D, Hamiwka L, McMahon JM, et al. De novo SCN1A mutations in migrating partial seizures of infancy. *Neurology* 2011;77:380-383.
18. Freilich ER, Jones JM, Gaillard WD, et al. Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy. *Arch Neurol* 2011;68:665-671.

19. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. *Nat Genet.* 2012 Nov;44(11):1255-9.
20. Sadleir LG, Mountier EI, Gill D, et al. Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype. *Neurology* 2017;89:1035-1042.
21. Geza Berecki P, Alexander Bryson, Jan Terhag, Snezana Maligevic, Elena V. Gazina, Sean L. Hill, Steven Petrou. SCN1A gain-of-function in early infantile encephalopathy. *Annals of Neurology* 2019; In press.
22. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. *Brain* 1997;120 (Pt 3):479-490.
23. Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? *Epilepsia* 2001;42:837-844.
24. Zhang YH, Burgess R, Malone JP, et al. Genetic epilepsy with febrile seizures plus: Refining the spectrum. *Neurology* 2017;89:1210-1219.
25. Myers KA, Burgess R, Afawi Z, et al. De novo SCN1A pathogenic variants in the GEFS+ spectrum: Not always a familial syndrome. *Epilepsia* 2017;58:e26-e30.
26. Sijben AE, Sithinamsuwan P, Radhakrishnan A, et al. Does a SCN1A gene mutation confer earlier age of onset of febrile seizures in GEFS+? *Epilepsia* 2009;50:953-956.
27. Allen AS, Bellows ST, Berkovic SF, et al. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. *The Lancet Neurology* 2017;16:135-143.
28. International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. *The Lancet Neurology* 2014;13:893-903.
29. International League Against Epilepsy Consortium on Complex E. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. *Nat Commun* 2018;9:5269.
30. Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. *Lancet Neurol* 2011;10:457-470.
31. Pietrobon D, Moskowitz MA. Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. *Nat Rev Neurosci* 2014;15:379-393.
32. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. *Lancet* 2005;366:371-377.
33. Castro MJ, Stam AH, Lemos C, et al. First mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and epilepsy. *Cephalalgia* 2009;29:308-313.

34. Mantegazza M, Cestele S. Pathophysiological mechanisms of migraine and epilepsy: Similarities and differences. *Neurosci Lett* 2018;667:92-102.
35. Catterall WA, Kalume F, Oakley JC. Nav1.1 channels and epilepsy. *J Physiol* 2010;588:1849-1859.
36. Hedrich UB, Liautard C, Kirschenbaum D, et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation. *J Neurosci* 2014;34:14874-14889.
37. Dhifallah S, Lancaster E, Merrill S, et al. Gain of Function for the SCN1A/hNav1.1-L1670W Mutation Responsible for Familial Hemiplegic Migraine. *Front Mol Neurosci* 2018;11:232.
38. O'Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. *Nat Genet* 2011;43:585-589.
39. D'Gama AM, Pochareddy S, Li M, et al. Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates Multiple Genetic Mechanisms. *Neuron* 2015;88:910-917.
40. Ouss L, Leunen D, Laschet J, et al. Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype. *Epilepsia Open* 2019;4:40-53.
41. Li BM, Liu XR, Yi YH, et al. Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. *Epilepsy Behav* 2011;21:291-295.
42. Berkvens JJ, Veugen I, Veendrick-Meekes MJ, et al. Autism and behavior in adult patients with Dravet syndrome (DS). *Epilepsy Behav* 2015;47:11-16.
43. Catterall WA. Dravet Syndrome: A Sodium Channel Interneuronopathy. *Curr Opin Physiol* 2018;2:42-50.
44. Oakley JC, Kalume F, Catterall WA. Insights into pathophysiology and therapy from a mouse model of Dravet syndrome. *Epilepsia* 2011;52 Suppl 2:59-61.
45. Kaplan JS, Stella N, Catterall WA, et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. *Proc Natl Acad Sci U S A* 2017;114:11229-11234.
46. Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected death in epilepsy. *Epilepsia* (2012) 53(2):227-33.
47. Bagnall RD, Crompton DE, Semsarian C. Genetic Basis of Sudden Unexpected Death in Epilepsy. *Front Neurol*. 2017 Jul 20;8:348. doi: 10.3389/fneur.2017.00348. eCollection 2017. Review.
48. Hindocha N, Nashef L, Elmslie F, et al. Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. *Epilepsia*. 2008;49:360-365.
49. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. *Epilepsia*. 2011;52(Suppl. 2):S44-S49.

50. Skluzacek JV, Watts KP, Parsy O, et al. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. *Epilepsia*. 2011;52(Suppl. 2):S95–S101.
51. Sakauchi M, Oguni H, Kato I, et al. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. *Epilepsia*. 2011;52:1144–1149.
52. Delogu AB, Spinelli A, Battaglia D, et al. Electrical and autonomic cardiac function in patients with Dravet syndrome. *Epilepsia*. 2011;52(Suppl. 2):S55–S58.
53. Ergul Y, Ekici B, Tatli B, et al. QT and P wave dispersion and heart rate variability in patients with Dravet syndrome. *Acta Neurol Belg*. 2013;113:161–166.
54. Cheah CS, Yu FH, Westenbroek RE, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. *Proc Natl Acad Sci U S A*. 2012;109:14646–14651. [PMC free article] [PubMed] [Google Scholar]
55. Kalume F, Westenbroek RE, Cheah CS, et al. Sudden unexpected death in a mouse model of Dravet syndrome. *J Clin Invest*. 2013;123:1798–1808.
56. Ogiwara I, Iwasato T, Miyamoto H, et al. Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndrome. *Hum Mol Genet*. 2013;22:4784–4804.
57. Auerbach DS, Jones J, Clawson BC, et al. Altered cardiac electrophysiology and SUDEP in a model of Dravet syndrome. *PLoS ONE*. 2013;8:e77843.
58. Goldman AM, Behr ER, Semsarian C, Bagnall RD, Sisodiya S, Cooper PN. Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention. *Epilepsia*. 2016 Jan;57 Suppl 1:17-25.
59. Brownstein CA, Goldstein RD, Thompson CH, et al. SCN1A variants associated with sudden infant death syndrome. *Epilepsia*. 2018 Apr;59(4):e56-e62.
60. Halvorsen M, Petrovski S, Shellhaas R, et al. Mosaic mutations in early-onset genetic diseases. *Genetics in Medicine*. 2016;18(7):746–749.
61. Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. *Orphanet J Rare Dis* 2013;8:176.
62. Villas N, Meskis MA, Goodliffe S. Dravet syndrome: Characteristics, comorbidities, and caregiver concerns. *Epilepsy Behav* 2017;74:81-86.
63. Nabbout R, Camfield CS, Andrade DM, et al. Treatment issues for children with epilepsy transitioning to adult care. *Epilepsy Behav* 2017;69:153-160.
64. Nabbout R, Auvin S, Chiron C, et al. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome. *Epilepsy Behav* 2018;78:232-242.

65. Nabbout R, Auvin S, Chiron C, et al. Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures. *Dev Med Child Neurol* 2019 Oct;61(10):1229-1236..

Author Manuscript